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 Introduction 
The Department of Health asked the National Institute for Health and Clinical 
Excellence (NICE or the Institute) to produce public health guidance on 
workplace health promotion with reference to smoking and what works in 
motivating and changing employees’ behaviour.  
The guidance is for NHS and non-NHS professionals and employers who 
have a role in – or responsibility for – supporting and encouraging employees 
who smoke to quit. This includes those working in local authorities and the 
community, voluntary and private sectors.  
The Public Health interventions Advisory Committee (PHIAC) has considered 
a review of the evidence, an economic appraisal, a survey of current practice 
and stakeholder comments in developing these recommendations.  
Details of PHIAC membership are given in appendix C. The methods used to 
develop the guidance are summarised in appendix D. Supporting documents 
used in the preparation of this document are listed in appendix E. Full details 
of the evidence collated, including stakeholder comments, are available on the 
NICE website, along with a list of the stakeholders involved and the Institute’s 
supporting process and methods manuals. The website address is: 
www.nice.org.uk
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 1 Recommendations 
This document constitutes the Institute’s formal guidance on how to 
encourage and support employees to stop smoking. 
The recommendations in this section are presented without any reference to 
evidence statements. Appendix A repeats the recommendations and lists their 
linked evidence statements. 
Reducing smoking and tobacco-related harm is a key government strategy for 
improving the health of people in England and reducing health inequalities. 
After 1 July 2007, smoking will be prohibited in virtually all enclosed public 
places and workplaces in England. This includes vehicles used for business 
and any rooms or shelters previously set aside for smoking (if they are 
enclosed or substantially enclosed, according to the definition of the law). 
Failure to comply will be an offence.  
Employers are not legally obliged to help employees to stop smoking. 
However, employers that do provide cessation support could reduce the risk 
of non-compliance with the law, as well as taking advantage of the opportunity 
it offers to improve people’s health. They will be promoting healthy living and 
no smoking within society, as well as benefiting from reduced sickness 
absence and increased productivity.  
The following smoking cessation interventions, as defined below, have been 
proven to be effective. 
Brief interventions  
Brief interventions for smoking cessation involve opportunistic advice, 
discussion, negotiation or encouragement and are delivered by a range of 
primary and community care professionals, typically within 5–10 minutes. The 
package provided depends on a number of factors including the individual’s 
willingness to quit, how acceptable they find the intervention and previous 
methods they have used. It may include one or more of the following: 
• simple opportunistic advice  
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 • an assessment of the individual’s commitment to quit 
• pharmacotherapy and/or behavioural support  
• self-help material  
• referral to more intensive support such as the NHS Stop Smoking Services. 
(NICE 2006a: www.nice.org.uk/PHI001  
NICE 2006b: http://guidance.nice.org.uk/page.aspx?o=389417). 
Individual behavioural counselling 
This is a face to face encounter between someone who smokes and a 
counsellor trained in assisting smoking cessation.  
(Lancaster and Stead 2005a: 
www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001292/frame.
html NICE 2006b: http://guidance.nice.org.uk/page.aspx?o=389417  
NICE 2006c: www.nice.org.uk/page.aspx?o=404427) 
Group behaviour therapy 
Group behaviour therapy programmes involve scheduled meetings where 
people who smoke receive information, advice and encouragement and some 
form of behavioural intervention (for example, cognitive behavioural therapy) 
delivered over at least two sessions.  
(NICE 2006b: http://guidance.nice.org.uk/page.aspx?o=389417 
NICE 2006c: www.nice.org.uk/page.aspx?o=404427 
Stead and Lancaster 2005: 
www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001007/frame.
html)  
Pharmacotherapies 
Stop smoking advisers and healthcare professionals may recommend and 
prescribe nicotine replacement therapy (NRT) or bupropion as an aid to help 
people to quit smoking, along with giving advice, encouragement and support. 
Before prescribing a treatment, they take into account the person’s intention 
and motivation to quit and how likely it is they will follow the course of 
treatment. They also consider which treatments the individual prefers, whether 
they have attempted to stop before (and how), and if there are medical 
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 reasons why they should not be prescribed NRT or bupropion.  
(NICE 2002: www.nice.org.uk/TA039  
NICE 2006b: http://guidance.nice.org.uk/page.aspx?o=389417) 
Self-help materials 
Self-help materials comprise any manual or structured programme, in written 
or electronic format, that can be used by individuals in a quit attempt without 
the help of health professionals, counsellors or group support. Materials can 
be aimed at anyone who smokes, particular populations (for example, certain 
age or ethnic groups) or may be interactively tailored to individual need. 
(Lancaster and Stead 2005b:  
www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001118/frame.
html NICE 2006b: http://guidance.nice.org.uk/page.aspx?o=389417) 
Telephone counselling and quitlines 
Telephone counselling and quitlines provide proactive or reactive advice, 
encouragement and support over the telephone to anyone who smokes who 
wants to quit, or who has recently quit.  
(Stead et al 2006: 
www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD002850/frame.
html NICE 2006b: http://guidance.nice.org.uk/page.aspx?o=389417 
NICE 2006c: www.nice.org.uk/page.aspx?o=404427)  
Recommendation 1 
Who should take action? 
Employers. 
What action should they take? 
• Publicise the interventions identified in this guidance and make 
information on local stop smoking support services widely available at 
work. This information should include details on the type of help 
available, when and where, and how to access the services.  
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 • Be responsive to individual needs and preferences. Where feasible, 
and where there is sufficient demand, provide on-site stop smoking 
support. 
• Allow staff to attend smoking cessation services during working hours 
without loss of pay.  
• Develop a smoking cessation policy in collaboration with staff and their 
representatives as one element of an overall smokefree workplace 
policy.  
Recommendation 2 
Who should take action? 
Employees who want to stop smoking. 
What action should they take?  
Contact local smoking cessation services, such as the NHS Stop Smoking 
Services, for information, advice and support.   
Recommendation 3 
Who should take action? 
Employees and their representatives. 
What action should they take?  
Encourage employers to provide advice, guidance and support to help 
employees who want to stop smoking. 
Recommendation 4 
Who should take action? 
All those offering smoking cessation services including the NHS, independent 
or commercial organisations and employers. 
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 What action should they take? 
• Offer one or more interventions that have been proven to be effective 
(see above). 
• Ensure smoking cessation support and treatment is delivered only by 
staff who have received training that complies with the ‘Standard for 
training in smoking cessation treatments’ 
(www.nice.org.uk/page.aspx?o=502591).  
• Ensure smoking cessation support and treatment is tailored to the 
employee’s needs and preferences, taking into account their 
circumstances and offering locations and schedules to suit them. 
Recommendation 5 
Who should take action? 
Managers of NHS Stop Smoking Services. 
What action should they take? 
• Offer support to employers who want to help their employees to stop 
smoking. Where appropriate and feasible, provide support on the 
employer’s premises.  
• If initial demand exceeds the resources available, focus on the 
following:  
− small and medium-sized enterprises (SMEs)  
− enterprises where a high proportion of employees are on low 
pay 
− enterprises where a high proportion of employees are from a 
disadvantaged background  
− enterprises where a high proportion of employees are heavy 
smokers. 
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 Recommendation 6 
Who should take action? 
Strategic health authorities and primary care trusts. 
What action should they take? 
Ensure local NHS Stop Smoking Services are able to respond to fluctuations 
in demand, particularly before and after implementation of smokefree 
legislation. 
2 Public health need and practice 
Smoking is the main cause of preventable illness and premature death in 
England. It led to an estimated annual average of 86,500 deaths between 
1998 and 2002 (Twigg et al. 2004). It is also a major factor contributing to 
health inequalities.  
A wide range of diseases and conditions are caused by smoking including: 
cancers, respiratory disease, coronary heart and other circulatory diseases, 
stomach/duodenal ulcer, impotence and infertility, complications in pregnancy 
and low birthweight. Following surgery, it contributes to lower survival rates, 
post-operative respiratory complications and poor healing.  
Breathing secondhand smoke (‘passive smoking’) can affect the health of 
non-smokers. For example, it can exacerbate respiratory problems and trigger 
asthma attacks. Longer term, it increases the risk of lung cancer, respiratory 
illnesses (especially asthma), heart disease and stroke (International Agency 
for Research on Cancer 2002; Scientific Committee on Tobacco and Health 
2004; US Environmental Protection Agency 1993).  
The scientific evidence indicates that there is no risk-free level of exposure to 
secondhand smoke (US Surgeon General 2006). Exposure in the workplace 
is estimated to be responsible for the deaths of 617 employees per year in the 
UK (about two employed people per working day) (Jamrozik 2005). 
Smoking is estimated to cost the NHS in England up to £1.5 billion a year 
(Parrott et al. 1998). Extrapolating from a study in Scotland (Parrott et al. 
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 2000) it costs industry a further £5 billion in terms of lost productivity, higher 
rates of absenteeism among people who smoke and fire damage.  
Reducing levels of smoking among employees will help reduce some illnesses 
and conditions (such as cardiovascular disease and respiratory diseases) that 
are important causes of sickness absence. This will result in improved 
productivity and less costs for employers.  
The workplace has several advantages as a setting for smoking cessation 
interventions:  
• large numbers of people can be reached (including groups who may not 
normally consult health professionals, such as young men)  
• there is the potential to provide peer group support  
• a no smoking working environment encourages people who smoke to quit.  
Policy background 
The Government’s independent Scientific Committee on Tobacco and Health 
(SCOTH) first summarised the health evidence on secondhand smoke and 
recommended smokefree workplaces in 1998 (SCOTH 1998). The tobacco 
white paper ‘Smoking kills’ (DH 1998) reinforced the message that people 
should not have to be exposed to cigarette smoke. But in 2004, about half of 
British workplaces still allowed some degree of smoking on the premises 
(Lader 2005).  
Shifting the balance towards smokefree workplaces and public places has 
become a key aspect of the government’s health strategy, as highlighted in 
the public health white paper ‘Choosing health’ (DH 2004). Virtually all 
workplaces in England will become smokefree when the regulations resulting 
from the 2006 Health Act come into force on 1 July 2007. 
3 Considerations 
PHIAC took account of a number of factors and issues in making the 
recommendations. 
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 3.1 Organisations which encourage and support employees who smoke to 
quit will benefit from a more productive workforce, improvements in staff 
morale and a healthier, smokefree environment. They will also help to 
promote no smoking within society. 
3.2 PHIAC has drawn on three sources of evidence to identify a wide range 
of proven smoking cessation interventions. These comprise: ‘Cochrane 
reviews of smoking cessation’; reviews of effectiveness carried out for 
the NICE smoking cessation programme (currently in development); and 
the ‘NICE evidence review for workplace interventions to promote 
smoking cessation’. Methods that have been proven to be effective in 
other settings also appear to be effective in the workplace. 
3.3 Currently, smoking cessation services are least likely to attract people 
from sectors of the population where smoking rates are particularly high. 
If services fail to address this inequity adequately, health inequalities are 
likely to increase. 
3.4 It often takes several attempts to quit smoking permanently and people 
need encouragement and support throughout this process. They also 
need congratulating once they have quit.  
3.5 Based on experience in other countries where similar legislation has 
been introduced, NHS Stop Smoking Services will need advance notice 
of any media or public relations activities introduced in relation to the 
legislation.  
 
In both the Republic of Ireland and Scotland, demand for help to stop 
smoking increased dramatically in response to publicity before the 
smokefree legislation came into force. However, it declined following 
implementation of the legislation. This suggests there may be an initial 
surge in demand from people who smoke in England. Services may wish 
to consider a range of approaches to meet this demand and so 
maximise the opportunity it offers to improve people’s health. These 
could include providing on-site services and recruiting trained advisers 
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 who can offer support both in the workplace and the community. 
3.6 It is important that the DH ensures that the database of NHS Stop 
Smoking Services is publicly available and is kept up to date. The 
services and their location need to be publicised so that employers can 
provide their employees with the help they need to quit.  
3.7 PHIAC notes that employers may need encouragement to provide their 
employees with smoking cessation support. This may be achieved by 
persuading business leaders of the benefits of investing in employee 
health. 
4 Implementation 
The Healthcare Commission assesses the performance of NHS organisations 
in meeting core and developmental standards set by the DH in ‘Standards for 
better health’ issued in July 2004 and updated in 2006. The implementation of 
NICE public health guidance will help organisations meet the standards in the 
public health (seventh) domain in ‘Standards for better health’. These include 
the core standards numbered C22 and C23 and the developmental standard 
D13. In addition, implementation of NICE public health guidance will help 
meet the health inequalities target as set out in ‘The NHS in England: the 
operating framework for 2006/7’ (DH 2006). 
NICE has developed tools to help organisations implement this guidance. The 
tools will be available on our website (www.nice.org.uk/PHI005). 
• Costing tools: 
− business case for supporting employees to quit smoking. 
• Other tools: 
− a slide set for smoking cessation services and employers 
highlighting key messages for local discussion 
− information sheet for employers explaining how NICE 
guidance can support compliance with smokefree legislation 
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 − practical advice for smoking cessation services on how to 
implement the guidance and details of national initiatives that 
can provide support. 
5 Recommendations for research 
PHIAC recommends that the following research questions should be 
addressed in order to improve the evidence relating to workplace smoking 
cessation.  
1. What are the most effective and cost-effective smoking cessation 
interventions for different sectors of the workforce including: 
• men and women  
• younger and older workers 
• minority ethnic groups  
• temporary/casual workers  
• employees who, as part of their job, go into the homes of people 
who smoke.  
2. What are the most effective and cost effective ways for employers to 
encourage and support employees who smoke to quit? 
3. How can employers be encouraged to provide smoking cessation 
support? 
4. What are the short and long-term benefits for employers of providing 
staff with smoking cessation support and treatment? 
5. How can local NHS Stop Smoking Services provide employees of 
small, medium and large enterprises with effective and cost-effective 
smoking cessation support and treatments? 
More detail on the evidence gaps identified during the development of this 
guidance is provided in appendix B. 
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 6 Updating the recommendations  
These recommendations will be updated in April 2008. 
7 Related guidance 
Published  
Guidance on the use of nicotine replacement therapy (NRT) and bupropion for 
smoking cessation. NICE technology appraisal 39 (2002). Available from: 
www.nice.org.uk/TA039  
Brief interventions and referral for smoking cessation in primary care and 
other settings. NICE public health intervention guidance 1 (2006). Available 
from: www.nice.org.uk/PHI001  
Under development 
Varenicline for smoking cessation. NICE technology appraisal guidance (due 
July 2007). 
Generic and specific interventions to support attitude and behaviour change at 
population and community levels. NICE public health programme guidance 
(due October 2007). 
The optimal provision of smoking cessation services, including the provision of 
nicotine replacement therapy (NRT) for primary care, pharmacies, local 
authorities and workplaces, with particular reference to manual working 
groups, pregnant women who smoke and hard to reach communities. NICE 
public health programme guidance (due November 2007). 
Preventing the uptake of smoking among children and young people, 
including point of sale measures. NICE public health intervention guidance 
(due June 2008). 
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 Appendix A: recommendations for policy and practice 
and supporting evidence statements 
This appendix sets out the recommendations and the associated evidence 
statements taken from a review of effectiveness, a review of the economic 
literature and an economic model (see appendix D for the key to study types 
and quality assessments). It also includes details of a survey of current 
practice.   
Recommendations are followed by the evidence statement(s) underpinning 
them. For example: [evidence statement number 1] indicates that the linked 
statement is numbered 1 in the review ‘Summary of evidence of effectiveness 
of smoking cessation interventions in the workplace’. Where a 
recommendation is not directly taken from the evidence statements, but is 
inferred from the evidence, this is indicated by IDE (inference derived from the 
evidence). 
The following smoking cessation interventions, as defined below, have been 
proven to be effective. 
Brief interventions  
Brief interventions for smoking cessation involve opportunistic advice, 
discussion, negotiation or encouragement and are delivered by a range of 
primary and community care professionals, typically within 5–10 minutes. The 
package provided depends on a number of factors including the individual’s 
willingness to quit, how acceptable they find the intervention and previous 
methods they have used. It may include one or more of the following: 
• simple opportunistic advice  
• an assessment of the individual’s commitment to quit 
• pharmacotherapy and/or behavioural support  
• self-help material  
• referral to more intensive support such as the NHS Stop Smoking Services. 
(NICE 2006a: www.nice.org.uk/PHI001  
NICE 2006b: http://guidance.nice.org.uk/page.aspx?o=389417). 
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 Individual behavioural counselling 
This is a face to face encounter between someone who smokes and a 
counsellor trained in assisting smoking cessation.  
(Lancaster and Stead 2005a: 
www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001292/frame.
html NICE 2006b: http://guidance.nice.org.uk/page.aspx?o=389417  
NICE 2006c: www.nice.org.uk/page.aspx?o=404427) 
Group behaviour therapy 
Group behaviour therapy programmes involve scheduled meetings where 
people who smoke receive information, advice and encouragement and some 
form of behavioural intervention (for example, cognitive behavioural therapy) 
delivered over at least two sessions.  
(NICE 2006b: http://guidance.nice.org.uk/page.aspx?o=389417 
NICE 2006c: www.nice.org.uk/page.aspx?o=404427 
Stead and Lancaster 2005: 
www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001007/frame.
html)  
Pharmacotherapies 
Stop smoking advisers and healthcare professionals may recommend and 
prescribe nicotine replacement therapy (NRT) or bupropion as an aid to help 
people to quit smoking, along with giving advice, encouragement and support. 
Before prescribing a treatment, they take into account the person’s intention 
and motivation to quit and how likely it is they will follow the course of 
treatment. They also consider which treatments the individual prefers, whether 
they have attempted to stop before (and how), and if there are medical 
reasons why they should not be prescribed NRT or bupropion.  
(NICE 2002: www.nice.org.uk/TA039  
NICE 2006b: http://guidance.nice.org.uk/page.aspx?o=389417) 
Self-help materials 
Self-help materials comprise any manual or structured programme, in written 
or electronic format, that can be used by individuals in a quit attempt without 
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 the help of health professionals, counsellors or group support. Materials can 
be aimed at anyone who smokes, particular populations (for example, certain 
age or ethnic groups) or may be interactively tailored to individual need. 
(Lancaster and Stead 2005b:  
www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD001118/frame.
html NICE 2006b: http://guidance.nice.org.uk/page.aspx?o=389417) 
Telephone counselling and quitlines 
Telephone counselling and quitlines provide proactive or reactive advice, 
encouragement and support over the telephone to anyone who smokes who 
wants to quit, or who has recently quit.  
(Stead et al 2006: 
www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD002850/frame.
html NICE 2006b: http://guidance.nice.org.uk/page.aspx?o=389417 
NICE 2006c: www.nice.org.uk/page.aspx?o=404427)  
Recommendation 1 
Who should take action? 
Employers. 
What action should they take? 
• Publicise the interventions identified in this guidance and make 
information on local stop smoking support services widely available at 
work. This information should include details on the type of help 
available, when and where, and how to access the services.  
• Be responsive to individual needs and preferences. Where feasible, 
and where there is sufficient demand, provide on-site stop smoking 
support. 
• Allow staff to attend smoking cessation services during working hours 
without loss of pay.  
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 • Develop a smoking cessation policy in collaboration with staff and their 
representatives as one element of an overall smokefree workplace 
policy.  
(Evidence statements 1, 2, 5, 6, 7, 8, 10, 11, 12, 13, 15, IDE) 
Recommendation 2 
Who should take action? 
Employees who want to stop smoking. 
What action should they take?  
Contact local smoking cessation services, such as the NHS Stop Smoking 
Services, for information, advice and support.   
(IDE) 
Recommendation 3 
Who should take action? 
Employees and their representatives. 
What action should they take?  
Encourage employers to provide advice, guidance and support to help 
employees who want to stop smoking. 
(IDE) 
Recommendation 4 
Who should take action? 
All those offering smoking cessation services including the NHS, independent 
or commercial organisations and employers. 
What action should they take? 
• Offer one or more interventions that have been proven to be effective 
(see above). 
• Ensure smoking cessation support and treatment is delivered only by 
staff who have received training that complies with the ‘Standard for 
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 training in smoking cessation treatments’ 
(www.nice.org.uk/page.aspx?o=502591).  
• Ensure smoking cessation support and treatment is tailored to the 
employee’s needs and preferences, taking into account their 
circumstances and offering locations and schedules to suit them. 
(Evidence statements 1, 2, 5, 6, 7, 8, 11, 13) 
Recommendation 5 
Who should take action? 
Managers of NHS Stop Smoking Services. 
What action should they take? 
• Offer support to employers who want to help their employees to stop 
smoking. Where appropriate and feasible, provide support on the 
employer’s premises.  
• If initial demand exceeds the resources available, focus on the 
following:  
− small and medium-sized enterprises (SMEs)  
− enterprises where a high proportion of employees are on low 
pay 
− enterprises where a high proportion of employees are from a 
disadvantaged background  
− enterprises where a high proportion of employees are heavy 
smokers. 
(Evidence statements 1, 2, 16) 
Recommendation 6 
Who should take action? 
Strategic health authorities and primary care trusts. 
What action should they take? 
Ensure local NHS Stop Smoking Services are able to respond to fluctuations 
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 in demand, particularly before and after implementation of smokefree 
legislation. 
(Survey of current practice) 
Evidence statements 
Evidence statement 1 
Although there are no available studies exploring which workplace 
interventions are most effective in the context of smokefree legislation, one  
2 (+) study of a variety of workplace intervention types, offered in the context 
of a localised smoking ban found that more intensive interventions (for 
example, group treatment and 1-hour clinics) produce higher success rates 
than less intensive interventions (for example, brief individual counselling and 
self-help manuals). It is unclear how readily these findings translate to 
workplaces in jurisdictions where comprehensive smokefree legislation has 
been introduced.  
Evidence statement 2 
A 1 (++) systematic review and a 1 (+) meta-analysis of the available 
international literature indicates that the most effective smoking cessation 
interventions in workplace settings are those interventions that have proven 
effectiveness more broadly. There is strong evidence that group therapy, 
individual counselling and pharmacological treatments all have an effect in 
facilitating smoking cessation. However, both reviews failed to identify effects 
due to particular intervention type. There is also evidence that minimal 
interventions, including brief advice from a health professional, are effective. 
Self-help manuals appear to be less effective, although there is limited 
evidence that interventions tailored to the individual have some effect. 
Evidence statement 5  
A 1 (+) study and a 2 (++) study found that men and women were equally 
successful in achieving abstinence in workplace smoking cessation 
programmes; however, important gender differences were apparent in 
smoking attitudes and behaviours. Women had less confidence in their ability 
to quit and required extra stimuli in order to quit smoking. Although these 
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 findings are based on American studies, they are likely to be broadly 
applicable to a UK setting. 
Evidence statement 6 
Although no studies were identified in the literature search that specifically 
address effective workplace interventions for younger and older smokers, 
evidence from a 2 (++) study indicates that older smokers are more likely to 
achieve successful abstinence in workplace interventions than younger 
smokers (although these employees were also more likely to be managers 
and light smokers). Furthermore, two 2 (+) studies examined the impact of 
age and job stress on cessation. Results from one study revealed that 
younger employees benefited more from higher demands than older 
employees with regards to smoking cessation. However, these findings were 
not supported in the other 2 (+) study. Therefore, although further research is 
needed in this area, it may be possible that younger employees who smoke 
require more intensive support for smoking cessation than older smokers, and 
that specifically tailoring interventions based on age may be beneficial. 
Although these findings are based on American studies, they are likely to be 
broadly applicable to a UK setting. 
Evidence statement 7 
A 2 (+) study found that although there are ethnic differences in baseline 
smoking patterns and attitudes towards cessation, ethnicity was not a 
significant predictor of successful abstinence. Another 1 (+) study found that a 
tailored intervention which incorporated linguistically and culturally appropriate 
materials, was effective in promoting behaviour change in a working class 
multi-ethnic population. Although these studies are from the USA, which has a 
different ethnic composition to the UK, it is likely that their findings are broadly 
applicable to a UK setting.  
Evidence statement 8 
No studies were identified in the literature search that specifically addressed 
effective workplace interventions for temporary or casual workers. As 
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 delivering workplace interventions to this population pose a significant 
challenge, research is urgently needed in this area.  
Evidence statement 10 
Various 4 (+) sources have indicated that creating and enforcing a smoking 
compliance strategy is an effective way to increase compliance. Specific tips 
for enforcing smokefree policy include providing training on how to enforce the 
policy, establishing links between the policy and HR policies, increasing 
awareness of the consequences of breaching policy, providing reminders that 
it is a criminal offence not to comply with smokefree legislation and notifying 
staff that action will be taken if someone is in breach of the policy. 
Evidence statement 11 
According to a 1 (++) systematic review, a key way that employers can 
encourage smokers to quit is by offering smoking cessation support. Such 
support is particularly important in the context of workplace smoking bans.  
A 2 (+) study concludes that because different types of smokers appear to 
choose different strategies for cessation, making a variety of smoking 
cessation strategies available to employees may meet the needs of more 
employees and increase participation in workplace programmes. 
Evidence statement 12 
Two 1 (++) systematic reviews of international studies indicate that financial 
incentives can support and encourage smokers to quit. While the addition of 
incentives does not appear to increase the quit rates of smoking cessation 
interventions in the workplace, there is evidence that such incentives do 
improve recruitment rates into worksite cessation programmes, which may 
lead to higher absolute numbers of successful quitters in the long term. 
Evidence statement 13 
According to a 2 (+) study, the majority of employed smokers are not ready to 
quit smoking. Therefore, smoking cessation materials and programmes need 
to recognise that smokers are at different stages of change rather than 
tailoring their materials only to those smokers who are highly motivated to 
quit. The researchers argue that proactive interventions are required, 
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 including access to subsidised pharmacological cessation aids, monetary 
incentives for assessment of smoking risk, direct personalised feedback, 
media/social marketing campaigns, and changes in the social norms and 
physical environment in the workplace, in public places, and in the home. 
Although this is an American study, its findings are likely to be broadly 
applicable to a UK setting. 
Evidence statement 15 
Two 2 (++) studies indicate that a key factor predicting whether a workplace 
will offer smoking cessation support is the personal attitude of the employer 
towards employee health. So, a key way of encouraging employers to provide 
smoking cessation support may be to directly target leaders and persuade 
them of the benefits of investing in employee health and the role it plays in 
company success. 
Evidence statement 16 
Two 2 (++) American studies, one 2 (-) Canadian study and one 2 (+) Scottish 
study provide strong evidence that small enterprises are far less likely to offer 
smoking cessation support than large enterprises. The findings of these 
studies suggest that small workplaces may have significant financial 
constraints that impede their ability to offer smoking cessation support and 
may also have characteristics that do not lend themselves to formal onsite 
programmes. Thus, unlike large enterprises, small enterprises have 
substantial needs in implementing smoking control activities in their worksite. 
As the conclusions of the US studies are echoed in a Scottish study, these 
findings are likely to be directly applicable to a UK setting. 
Survey of current practice 
Summary of findings from the experiences of smokefree Scotland and 
Ireland and a study of smoking cessation services in England  
The Scottish and Irish experience of introducing smokefree legislation 
suggests that the demand for smoking cessation services will increase in the 
run-up to the smoking ban in England on 1 July. It also suggests that this 
demand will be linked to media activity.   
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 Smoking cessation services are likely to face an increase in the number of 
employers wishing to use their services and an increase in demand direct 
from people who smoke. It is important to ensure resources are in place to 
meet the extra demand for smoking cessation services and treatments.  
Cost-effectiveness evidence  
Summary of findings from the literature review 
Overall, there is limited information on the cost effectiveness of workplace 
smoking cessation interventions, but the studies that were identified in the 
review suggest that they are cost effective. 
Summary of findings from modelling the health benefits  
The model aimed to estimate the cost effectiveness of smoking cessation 
interventions delivered in the workplace. These included:  
• brief advice  
• brief advice plus self-help material  
• brief advice, self-help material and advice on using nicotine replacement 
therapy (NRT)  
• brief advice, self-help material, advice on using NRT and specialist 
support. 
All interventions led to a reduction in the number of people who smoke, fewer 
comorbidities and more years of good health (QALYs) compared to ‘no 
intervention’. 
Summary of findings from modelling the net financial benefit to 
employers 
All interventions reduced the number of employees who smoke, leading to 
increased productivity compared to ‘no intervention’. Cessation rates were 
directly linked to productivity: a high cessation rate led to lower associated 
productivity losses.  
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 The net financial benefit for employers was calculated by subtracting the cost 
of the intervention from the productivity benefits. Most interventions begin to 
produce a net financial benefit after 2 years. Some of the cheaper 
interventions lead to a net financial benefit after 1 year.   
Full details of the surveys of current practice and reviews of cost effectiveness 
and modelling can be found on the NICE website (www.nice.org.uk/PHI005). 
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 Appendix B: gaps in the evidence 
PHIAC identified a number of gaps in the evidence relating to the 
interventions under examination, based on an assessment of the evidence 
and stakeholder comments. These gaps are set out below. 
1. The cost effectiveness of workplace interventions and the long-term 
benefits. 
2. Comparisons of the effectiveness of interventions for different sectors 
of the workforce such as men and women, younger and older workers, 
minority ethnic groups and temporary/casual workers.  
3. The effectiveness of workplace smoking cessation interventions in 
populous countries with national legislation that prohibits smoking in 
virtually all enclosed public places and workplaces. 
4. The ways that employers can encourage and support employees who 
smoke to quit.  
5. The ways that employers can be encouraged to provide smoking 
cessation support.  
6. The resource needs of small, medium and large employers with regard 
to providing smoking cessation support.  
7. The long-term business benefits of providing workplace smoking 
cessation support. 
The Committee made five recommendations for research. These are listed in 
section 5. 
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 Appendix C: membership of the Public Health 
Interventions Advisory Committee (PHIAC), the NICE 
Project Team and external contractors 
Public Health Interventions Advisory Committee 
NICE has set up a standing committee, the Public Health Interventions 
Advisory Committee (PHIAC), which reviews the evidence and develops 
recommendations on public health interventions.  
Membership of PHIAC is multidisciplinary, comprising public health 
practitioners, clinicians (both specialists and generalists), local authority 
employees, representatives of the public, patients and/or carers, academics 
and technical experts as follows.  
Mrs Cheryll Adams Professional Officer for Research and Practice 
Development with the Community Practitioners' and Health Visitors' 
Association (CPHVA) 
Professor Sue Atkinson CBE Independent Consultant and Visiting Professor 
in the Department of Epidemiology and Public Health, University College 
London 
Professor Michael Bury Emeritus Professor of Sociology at the University of 
London and Honorary Professor of Sociology at the University of Kent  
Professor Simon Capewell Chair of Clinical Epidemiology, University of 
Liverpool 
Professor K K Cheng Professor of Epidemiology, University of Birmingham 
Dr Richard Cookson Senior Lecturer, Department of Social Policy and Social 
Work, University of York 
Mr Philip Cutler Forums Support Manager, Bradford Alliance on Community 
Care 
Professor Brian Ferguson Director of the Yorkshire and Humber Public 
Health Observatory  
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 Professor Ruth Hall Regional Director, Health Protection Agency, South 
West 
Ms Amanda Hoey Director, Consumer Health Consulting Limited 
Mr Andrew Hopkin Senior Assistant Director for Derby City Council 
Dr Ann Hoskins Deputy Regional Director of Public Health for NHS North 
West 
Ms Muriel James Secretary for the Northampton Healthy Communities 
Collaborative and the King Edward Road Surgery Patient Participation Group 
Professor David R Jones Professor of Medical Statistics in the Department 
of Health Sciences, University of Leicester 
Dr Matt Kearney General Practitioner, Castlefields, Runcorn and GP Public 
Health Practitioner, Knowsley  
Ms Valerie King Designated Nurse for Looked After Children for Northampton 
PCT, Daventry and South Northants PCT and Northampton General Hospital. 
Public Health Skills Development Nurse for Northampton PCT 
CHAIR Dr Catherine Law Reader in Children’s Health, Institute of Child 
Health, University College London 
Ms Sharon McAteer Health Promotion Manager, Halton PCT 
Professor Klim McPherson Visiting Professor of Public Health 
Epidemiology, Department of Obstetrics and Gynaecology, University of 
Oxford 
Professor Susan Michie Professor of Health Psychology, BPS Centre for 
Outcomes Research & Effectiveness, University College London 
Dr Mike Owen General Practitioner, William Budd Health Centre, Bristol 
Ms Jane Putsey Lay Representative. Chair of Trustees of the Breastfeeding 
Network  
Dr Mike Rayner Director of British Heart Foundation Health Promotion 
Research Group, Department of Public Health, University of Oxford 
Mr Dale Robinson Chief Environmental Health Officer, South 
Cambridgeshire District Council 
Professor Mark Sculpher Professor of Health Economics at the Centre for 
Economics (CHE), University of York 
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 Dr David Sloan Retired Director of Public Health 
Dr Dagmar Zeuner Consultant in Public Health, Islington PCT 
Expert cooptees from the NICE Programme Development Group on 
Smoking Cessation  
Deborah Arnott Director of Action on Smoking and Health (ASH)  
Ian Gray Policy Officer – Health Development, Chartered Institute of 
Environmental Health  
Andrew Hayes Regional Tobacco Control Policy Manager, London  
Paul Hooper Regional Tobacco Control Policy Manager, West Midlands  
Sir Alexander Macara Chair of the NICE Programme Development Group on 
Smoking Cessation 
NICE Project Team 
Professor Mike Kelly 
CPHE Director 
Tricia Younger 
Associate Director  
Dr Lesley Owen 
Lead Analyst  
Patti White 
Analyst 
Dr Hugo Crombie 
Analyst 
Dr Alastair Fischer 
Health Economics Adviser. 
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 External contractors 
The British Columbia Centre of Excellence for Women’s Health carried out the 
review of effectiveness. The authors were; Dr Kirsten Bell, Lucy McCulloch, 
Karen DeVries, Dr Lorraine Greaves and Natasha Jategaonkar.   
Professor Ann McNeill and Adam Crosier carried out research on current 
service provision and provided expert testimony;  
The York Health Economics Consortium carried out the economic appraisal.  
The authors were: Paul Trueman, Sarah Flack and Dr Matthew Taylor. 
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 Appendix D: summary of the methods used to develop 
this guidance  
Introduction 
The reports of the review and economic analysis include full details of the 
methods used to select the evidence (including search strategies), assess its 
quality and summarise it.  
In addition, a study was commissioned on current service provision. The first 
part of the study examined NHS Stop Smoking Services in England through 
case studies and an on-line survey of NHS Stop Smoking Services 
coordinators. The second part of the study examined learning from Scotland 
and Ireland, following the introduction of legislation to make workplaces 
smokefree.  
The minutes of the PHIAC meetings provide further detail about the 
Committee’s interpretation of the evidence and development of the 
recommendations. 
All supporting documents are listed in appendix E and are available from the 
NICE website at: www.nice.org.uk/PHI005
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 The guidance development process 
The stages of the guidance development process are outlined in the box 
below: 
1. Draft scope  
2. Stakeholder meeting  
3. Stakeholder comments  
4. Final scope and responses published on website 
5. Reviews and cost-effectiveness modelling 
6. Synopsis report of the evidence (executive summaries and evidence tables) 
circulated to stakeholders for comment 
7. Comments and additional material submitted by stakeholders 
8. Review of additional material submitted by stakeholders (screened against 
inclusion criteria used in reviews)  
9. Synopsis, full reviews, supplementary reviews and economic modelling 
submitted to PHIAC 
10. PHIAC produces draft recommendations 
11. Draft recommendations published for comment by stakeholders on 
website  
12. PHIAC amends recommendations  
13. Responses to comments published on website 
14. Final guidance published on website 
Key questions 
The key questions were established as part of the scope. They formed the 
starting point for the reviews of evidence and facilitated the development of 
recommendations by PHIAC. The overarching question was:  
Which interventions are effective and cost effective in the workplace? 
The subsidiary questions were: 
• Which interventions work best in workplaces where comprehensive 
smokefree legislation has been introduced? 
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 • What are the most effective and appropriate interventions for different 
sectors of the workforce such as men and women, younger and older 
workers, minority ethnic groups and temporary/casual workers?  
• What are the most effective ways of encouraging employee compliance 
with a smokefree policy? 
•  How can employers support and encourage people who smoke to quit? 
• What support can employers offer people who smoke and who are not 
currently ready to quit? 
• How can employers be encouraged to provide smoking cessation support? 
• What are the resource needs of large, medium and small enterprises in 
implementing smokefree legislation and helping people who smoke to quit? 
• Which interventions are cost effective? 
Reviewing the evidence of effectiveness 
A review of effectiveness was conducted. 
Identifying the evidence  
The following databases were searched in four stages, as follows.  
Stage 1 
The search for systematic reviews and reviews was undertaken in the 
following databases for the years 1990–2006: Cochrane database of 
systematic reviews; DARE; National Research Register; Health Technology 
Assessment Database; SIGN Guidelines; National Guideline Clearinghouse; 
HSTAT; TRIP; Medline (1966–May 2006); Embase (1974–2006); CINAHL 
(1982–2006); British Nursing Index (1994–2006); PsycINFO (1806–2006); 
DH-Data (1983–2006); King’s Fund (1979–2006). 
Stage 2 
The search for other publications was undertaken in the following databases: 
Medline (1966–May 2006); Embase (1974–2006); CINAHL (1982–2006); 
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 British Nursing Index (1994–2006); PsycINFO (1806–2006); DH-Data (1983–
2006); King’s Fund (1979–2006); CENTRAL (2006/2). 
Stage 3 
A further search of Medline was undertaken for abstracts (as well as titles) of 
all publications. 
Stage 4 
A search was undertaken of the following websites to identify any additional 
reports and documents of relevance:   
• UK National Smoking Cessation Conference: www.uknscc.org/index.html 
(presentations were searched) 
• Department of Health: www.dh.gov.uk 
• National Health Service: www.nhs.uk 
• Action on Smoking and Health: www.ash.org.uk 
• Action on Smoking and Health Scotland: www.ashscotland.org.uk 
• Scottish Executive: www.scotland.gov.uk 
• Government of Ireland: www.irlgov.ie/ 
• Quit: www.quit.org.uk 
Further details of the databases, search terms and strategies are included in 
the review report.  
Selection criteria 
Studies were included if they covered:  
• people who smoke aged 16 and over  
• workplace smoking cessation interventions delivered either at work or 
externally.  
Studies were excluded if they described workplace health improvement 
programmes that did not include a smoking-related component.  
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 Outcomes of interest included non-validated and validated measures of 
smoking behaviour. In the case of Cochrane reviews, effectiveness studies 
were only included if they had a follow-up after 6 months or longer. 
Quality appraisal 
Included papers were assessed for methodological rigour and quality using 
the NICE methodology checklist, as set out in the NICE technical manual 
‘Methods for development of NICE public health guidance’ (see appendix E). 
Each study was described by study type (classified 1–4) and graded (++, +, -) 
to reflect the risk of potential bias arising from its design and execution. 
Study type 
1  Meta-analyses, systematic reviews of RCTs, or RCTs (including cluster  
RCTs). 
2  Systematic reviews of, or individual, non-randomised controlled trials,  
case-control studies, cohort studies, controlled before-and-after (CBA)  
studies, interrupted time series (ITS) studies, correlation studies. 
3  Non-analytic studies (for example, case reports, case series studies). 
4 Expert opinion, formal consensus. 
Study quality 
++  All or most criteria have been fulfilled. Where they have not been  
fulfilled the conclusions are thought very unlikely to alter. 
+  Some criteria fulfilled. Those criteria that have not been  
fulfilled or not adequately described are thought unlikely to alter the 
conclusions. 
–  Few or no criteria fulfilled. The conclusions of the study are  
thought likely or very likely to alter. 
Study design and quality were combined. For example, a type 1 study fulfilling 
most criteria and a type 2 study fulfilling very few criteria would appear in the 
format 1 (++) and 2 (-) respectively. Each review includes a number of 
evidence statements that reflect the strength (quantity, type and quality) of 
evidence. 
The studies were also assessed for their applicability to the UK.  
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 Summarising the evidence and making evidence statements 
The review data was summarised in evidence tables (see full reviews and 
synopsis). The findings from the review were synthesised and used as the 
basis for a number of evidence statements relating to each question. The 
evidence statements reflect the strength (quantity, type and quality) of the 
evidence and its applicability to the populations and settings in the scope. 
Economic appraisal 
The economic appraisal consisted of a review of economic evaluations and a 
cost-effectiveness analysis. 
Review of economic evaluations 
A systematic search was carried out on the NHS EED database and the 
Centre for Reviews and Dissemination (CRD) internal database. This was 
supplemented by material found in the effectiveness and cost-effectiveness 
reviews undertaken for the NICE smoking cessation programme (under 
development).  
The criteria for inclusion in the review were as follows: 
• studies included a specific intervention to assist smoking cessation 
• the study population was smoking at the start of the study (unless 
drawn from a general population) 
• studies reported on both the cost and effectiveness of the smoking 
cessation intervention (although cost and effectiveness was not 
necessarily combined into a single cost-effectiveness ratio). 
Ten studies met the inclusion criteria. These were assessed for their 
methodological rigour and quality using the critical appraisers’ checklists 
provided in appendix B of the ’Methods for development of NICE public health 
guidance’ (see table 3.1). Each study was categorised by study type and 
graded using a code (++), (+) or (-), based on the potential sources of bias.  
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 Cost-effectiveness analysis 
An economic model was constructed to incorporate data from the reviews of 
effectiveness and cost effectiveness. The results are reported in: ‘Cost 
effectiveness of interventions for smoking cessation’ (Flack et al. 2007a) and 
‘Cost impact analysis of workplace-based interventions for smoking cessation’ 
(Flack et al. 2007b). These reports are available on the NICE website at 
www.nice.org.uk/PHI005
How PHIAC formulated the recommendations 
At its meetings in November and December 2006, PHIAC considered the 
evidence of effectiveness and cost effectiveness and comments from 
stakeholders to determine: 
• whether there was sufficient evidence (in terms of quantity, quality and 
applicability) to form a judgement 
• whether, on balance, the evidence demonstrates that the interventions are 
effective or ineffective, or whether it is equivocal 
• where there is an effect, the typical size of effect. 
PHIAC developed draft recommendations through informal consensus, based 
on the following criteria: 
• Strength (quality and quantity) of evidence of effectiveness and its 
applicability to the populations/settings referred to in the scope. 
• Effect size and potential impact on population health and/or reducing 
inequalities in health. 
• Cost effectiveness (for the NHS and other public sector organisations). 
• Balance of risks and benefits. 
• Ease of implementation and the anticipated extent of change in practice 
that would be required. 
PHIAC also considered whether a recommendation should only be 
implemented as part of a research programme where evidence was lacking.  
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 Where possible, recommendations were linked to an evidence statement(s) 
(see appendix A for details). Where a recommendation was inferred from the 
evidence, this was indicated by the reference ‘IDE’ (inference derived from the 
evidence). 
The draft guidance including the recommendations was released for 
consultation in December 2006. The guidance was signed off by the NICE 
Guidance Executive in March 2007. 
 
 42
 Appendix E: supporting documents 
Supporting documents are available from the NICE website 
(www.nice.org.uk/PHI005). These include the following: 
• Review of effectiveness 
• Economic analysis: review and modelling report 
• Survey of current practice  
• A quick reference guide for professionals and employers whose remit 
includes supporting and encouraging employees who smoke to quit and for 
interested members of the public. This is also available from the NHS 
Response Line (0870 1555 455 – quote reference number N1188).  
Other supporting documents include: 
• ‘Methods for development of NICE public health guidance’ available from: 
www.nice.org.uk/phmethods 
• ‘The public health guidance development process: An overview for 
stakeholders including public health practitioners, policy makers and the 
public’ available from: www.nice.org.uk/phprocess 
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